Evidence map›Paper›PMID 36410793›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2023

Effects of hsa-miR-9-3p and hsa-miR-9-5p on Topoisomerase II

Jessika Carvajal-Moreno, Victor A Hernandez, Xinyi Wang, Junan Li, Jack C Yalowich, Terry S Elton

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. MircoRNAs predict and modulate responses to chemotherapy in leukemic patients.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  3. Article
  4. Use of CRISPR/Cas9 with Homology-Directed Repair to Gene-Edit Topoisomerase IIThe Journal of pharmacology and experimental therapeutics · 2024
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jessika Carvajal-MorenoDivision of Pharmaceutics and Pharmacology (J.C.-M., V.A.H., X.W., J.C.Y., T.S.E.) and Division of Outcomes and Translational Science (J.I.), College of Pharmacy, The Ohio State University, Columbus, Ohio.
Victor A HernandezDivision of Pharmaceutics and Pharmacology (J.C.-M., V.A.H., X.W., J.C.Y., T.S.E.) and Division of Outcomes and Translational Science (J.I.), College of Pharmacy, The Ohio State University, Columbus, Ohio.
Xinyi WangDivision of Pharmaceutics and Pharmacology (J.C.-M., V.A.H., X.W., J.C.Y., T.S.E.) and Division of Outcomes and Translational Science (J.I.), College of Pharmacy, The Ohio State University, Columbus, Ohio.
Junan LiDivision of Pharmaceutics and Pharmacology (J.C.-M., V.A.H., X.W., J.C.Y., T.S.E.) and Division of Outcomes and Translational Science (J.I.), College of Pharmacy, The Ohio State University, Columbus, Ohio.
Jack C YalowichDivision of Pharmaceutics and Pharmacology (J.C.-M., V.A.H., X.W., J.C.Y., T.S.E.) and Division of Outcomes and Translational Science (J.I.), College of Pharmacy, The Ohio State University, Columbus, Ohio yalowich.1@osu.edu elton.8@osu.edu.ORCID 0000-0001-5414-573X
Terry S EltonDivision of Pharmaceutics and Pharmacology (J.C.-M., V.A.H., X.W., J.C.Y., T.S.E.) and Division of Outcomes and Translational Science (J.I.), College of Pharmacy, The Ohio State University, Columbus, Ohio yalowich.1@osu.edu elton.8@osu.edu.ORCID 0000-0001-8034-8741
The Ohio State University · US

Funding

Novel Topoisomerase II alpha isoform as a drug resistance determinantR01CA226906 · NCI · OHIO STATE UNIVERSITY · PI ELTON, TERRY S, YALOWICH, JACK C. · 2019 to 2023
$1.8M
NCI NIH HHS R01 CA226906
6 · The paper itself

Abstract

DNA topoisomerase II

Indexed as

Antineoplastic AgentsLeukemiaMicroRNAsDNA Topoisomerases, Type IIEtoposideHumansK562 CellsPoly-ADP-Ribose Binding ProteinsRNA, MessengerAntineoplastic AgentsDNA Topoisomerases, Type IIEtoposideMicroRNAsMIRN92 microRNA, humanPoly-ADP-Ribose Binding ProteinsRNA, MessengerTOP2B protein, human

Identifiers

PMID36410793
PMCPMC9875313
OpenAlexW4309657661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.